Continuously taking these medicines may double the risk of stomach cancer

Share This Post

A study published in “Intestine” showed that long-term use of proton pump inhibitors will double the risk of gastric cancer . Proton pump inhibitors are a class of drugs used to treat gastric acid reflux. ,

Continuous use of this drug will eliminate Helicobacter pylori, which is closely related to the development of gastric cancer. In general, eliminating H. Helicobacter in the intestine can significantly reduce the risk of stomach cancer. But a considerable proportion of people still continue to develop gastric cancer. According to statistics, in recent years, gastric cancer has become the third leading cause of cancer death in the world.

Previously published research found a relationship between the use of proton pump inhibitors and increased risk of gastric cancer, but scientists have not been able to prove the potential role of H. pylori itself. In this study, scientists tried to bypass this problem. They compared the data of participants who used proton pump inhibitors with another type of drug. The first group of participants was the proton pump inhibitor group, and the second group of participants The data comes from the data of participants using histamine H2 receptor antagonists, which are a class of drugs used to inhibit acid production. The investigators followed them up for 7.5 years.

During this time, the researchers observed that although both groups of participants had chronic gastritis, the group using proton pump inhibitors doubled their risk of stomach cancer during the study period, while taking H2 receptors blocked Participants did not have high-risk changes. In addition, the researchers also found that more frequent use will bring greater risks, and daily use will increase the risk of gastric cancer by more than four times.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy for AIDS related B Cell malignancies
Aids cancer

CAR T Cell therapy for AIDS related B-Cell malignancies

CAR T cell therapy for HIV-related B cell malignancies involves genetically modifying a patient’s T cells to express chimeric antigen receptors (CARs) targeting CD19 on B cells. This treatment holds promise in eradicating malignant B cells but must carefully manage immunosuppression in HIV-positive individuals.

Cancer statistics in India 2024
Cancer

Cancer statistics in India 2024: Incidence, estimates and projections

In 2024, cancer will remain a significant health challenge in India. The country sees over 1.5 million new cases a year. Breast and oral cancers are most prevalent among women and men, respectively. Sadly, many cases are diagnosed late, impacting survival rates. Improved awareness and access to healthcare are crucial. By 2030, cancer incidence is expected to surpass 1.7 million cases annually. Efforts to enhance prevention, early detection, and treatment access are crucial to mitigate this growing burden. Check our cancer statistics in India for 2024 and future projections.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy